1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About Glaukos Corporation

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
Thomas Burns

229 Avenida Fabricante
San Clemente, California 92672-7531
Phone: 19493679600


Glaukos Corp president and COO sells over $280k in stock
Jun 05, 2024 23:38pm


Glaukos Governance and Compensation Strategy Evolves
Jun 05, 2024 12:02pm

An update from Glaukos (GKOS) is now available. Glaukos Corporation’s Board of Directors implemented the amended 2015 Omnibus Incentive Compensatio…

Adult Myopia Market Forecast 2032: FDA Approvals, Clinical Trials, Pipeline, Epidemiology and Companies by DelveInsight
May 28, 2024 14:58pm

Adult myopia companies are ORA, Inc., LENZ Therapeutics, Inc, Glaukos Corporation, Vyluma, Inc., Sydnexis, Ocumension limited, Santen Pharmaceutical, and more. ALBANY, NEW YORK, UNITED STATES, May 28, 2024 /⁨EINPresswire.com⁩/ -- DelveInsight’s …

Source:EIN News Healthcare
Eye Disease-Focused Glaukos'' ''Investor Interest Should Continue To Gain Momentum:'' Analyst
May 02, 2024 19:36pm

Thursday, Glaukos Corporation (NYSE: GKOS ) reported a first-quarter adjusted EPS loss of $(0.70), up from $(0.59) a year ago, missing the consensus of $(0.57) . The company reported sales of $85.6 million, up 16% Y/Y, beating the consensus of $79.6 million. Guidance: Glaukos expects 2024 sales of $357 million-$365 million, compared to the consensus of $357.934 million . William Blair reports that iDose exceeded expectations during its initial quarter of launch, with the iStent franchise experiencing growth in the mid-teens, surpassing expectations as well. The growth was driven by the demand for the iStent infinite product, which not only contributed to market expansion but also captured market share in the core combo-cataract segment. “Clearly, the glaucoma business is firing on all cylinders, and … Full story available on Benzinga.com

GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q1 2024
May 02, 2024 03:53am

Glaukos (NYSE: GKOS ) just reported results for the first quarter of 2024. Glaukos reported earnings per share of -70 cents. This was below the analyst estimate for EPS of -57 cents. The company reported revenue of $85.62 million. This was 7.57% better than the analyst estimate for revenue of $79.60 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at [email protected]. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. Legendary Investor Predicts: “Forget A.I.

Glaukos Corporation (GKOS) Q1 2024 Earnings Call Transcript
May 02, 2024 00:42am

No summary available.

Source:Seeking Alpha
Glaukos First-Quarter 2024 Financial Performance Overview
May 01, 2024 20:24pm

Glaukos (GKOS) has shared an update. Glaukos Corporation has released its first-quarter financial summary for 2024, offering investors a glimpse in…

Glaukos Announces the Release of its 2023 Sustainability Report
Apr 16, 2024 20:05pm

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2023 Sustainability Report. The report highlights the company’s continued commitment and progress on its key corporate sustainability initiatives. The Sustainability Jetzt den vollständigen Artikel lesen